Exploring the in situ expression of vascular endothelial growth factor and endoglin in pemphigus foliaceus variants and pemphigus vulgaris

Carregando...
Imagem de Miniatura
Citações na Scopus
2
Tipo de produção
article
Data de publicação
2018
Título da Revista
ISSN da Revista
Título do Volume
Editora
WILEY
Autores
ZOROQUIAIN, P.
DIAS, A. B. T.
MANSURE, J. J.
BURNIER JR., M. N.
Citação
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, v.32, n.11, p.1954-1958, 2018
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background Erythroderma is a severe manifestation of pemphigus foliaceus (PF), a blistering disease mediated by IgG autoantibodies against desmoglein 1. Increasing evidence supports the contribution of angiogenic mediators in the pathogenesis of erythroderma. ObjectiveMethodsTo evaluate the in situ expression of vascular endothelial growth factor (VEGF) and endoglin in patients with PF with erythroderma. Formalin-fixed paraffin-embedded skin samples obtained from patients with erythrodermic PF (n = 19; 12 patients with endemic PF), non-erythrodermic PF (n = 17), pemphigus vulgaris (PV; n = 10), psoriasis (n = 10) and healthy individuals (HI; n = 10) were processed in an automated immunohistochemistry platform utilizing anti-VEGF and anti-endoglin as primary antibodies. Reactivity was evaluated both manually (0 = negative; 1+ = mild; 2+ = intense) and through an automated microvessel analysis algorithm. ResultsConclusionVascular endothelial growth factor expression in erythrodermic PF was higher than in non-erythrodermic PF (P = 0.034) and in HI (P = 0.004), and similar to psoriasis (P = 0.667) and PV (P = 0.667). In non-erythrodermic PF, VEGF positivity was similar to HI (P = 0.247), and lower than psoriasis (P = 0.049) and PV (P = 0.049). Both erythrodermic and non-erythrodermic PF presented similar endoglin expression (P = 0.700). In addition, endoglin positivity during erythrodermic PF was similar to psoriasis (P = 0.133) and lower than PV (P = 0.0009). Increased expression of in situVEGF suggests that healing processes are triggered in response to tissue damage led by autoantibodies in PF, especially during erythroderma. Reduced endoglin positivity suggests that an unbalanced angiogenesis may occur during erythrodermic PF. Further studies may help to confirm if the regulation of VEGF and endoglin expression in patients with PF can contribute to control the healing process and enable disease remission. Overexpression of VEGF in erythrodermic PF as well as in PV and psoriasis points out a dysregulated repair process in severe forms of these diseases and suggests VEGF and endoglin could act as prognostic markers and future therapeutic targets to enable proper healing in PF.
Palavras-chave
Referências
  1. Ameglio F, 1997, J BIOL REG HOMEOS AG, V11, P148
  2. Aoki V, 2015, J DERMATOL, V42, P18, DOI 10.1111/1346-8138.12675
  3. Bae ON, 2015, BIOMOL THER, V23, P12, DOI 10.4062/biomolther.2014.102
  4. Bielefeld KA, 2013, CELL MOL LIFE SCI, V70, P2059, DOI 10.1007/s00018-012-1152-9
  5. BROWN LF, 1995, J INVEST DERMATOL, V104, P744, DOI 10.1111/1523-1747.ep12606974
  6. Creamer D, 1996, LANCET, V348, P1101, DOI 10.1016/S0140-6736(05)64447-9
  7. Kumar I, 2009, BRIT J SURG, V96, P1484, DOI 10.1002/bjs.6778
  8. Liu Z, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086273
  9. Martin P, 2015, BRIT J DERMATOL, V173, P370, DOI 10.1111/bjd.13954
  10. Miyamoto D, 2017, J EUR ACAD DERMATOL, V31, P333, DOI 10.1111/jdv.13905
  11. Miyamoto D, 2018, HUMAN PATHOLOGY CASE, V12, P1
  12. Perez-Gomez E, 2014, J INVEST DERMATOL, V134, P247, DOI 10.1038/jid.2013.263
  13. Valluru M, 2011, FRONT PHYSIOL, V2, DOI 10.3389/fphys.2011.00089
  14. Van de Kerkhof PCM, 1998, ACTA DERM-VENEREOL, V78, P19
  15. Viac J, 1997, ARCH DERMATOL RES, V289, P158, DOI 10.1007/s004030050172
  16. Wise LM, 2012, CELL MICROBIOL, V14, P1376, DOI 10.1111/j.1462-5822.2012.01802.x
  17. Zheng ZF, 2017, WOUND REPAIR REGEN, V25, P389, DOI 10.1111/wrr.12546